MedeliX
Start asking

Plerixafor

Mozobil · ATC code L03AX16

Also known as: Pleriksafor · Brand names: Mozobil, Plerixafor Stada, Plerixafor Teva, Plerixafor Viatris, Plerixafor Amarox, Plerixafor Puren, Plerixafor Ratiopharm, Plerixafor Seacross, Plerixafor Tillomed, Plerixafor Vivanta, Plerixafor Zentiva, Lexeva, Miyeleksor, Mozofor, Mozosent …

Key facts
Active substance
Plerixafor
Drug class
Cytovir-3
ATC code
L03AX16
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Mozobil 20 mg/ml solution for injection
Marketing authorisation holder
Sanofi B.V.
Information as of
2026-10-29

Key facts

Plerixafor (Mozobil) is a CXCR4 chemokine receptor antagonist used with G-CSF to mobilise haematopoietic stem cells into the blood for collection and autologous transplantation.

What it is used for

  • Adults with lymphoma or multiple myeloma whose cells mobilise poorly: with G-CSF to enhance stem cell mobilisation for collection and autologous transplantation.
  • Children (1 to less than 18 years) with lymphoma or solid malignant tumours: with G-CSF, either pre-emptively when the expected stem cell yield is insufficient, or after a previous failed collection.

Dosing

  • Adults: 20 mg fixed dose or 0.24 mg/kg body weight for patients weighing ≤ 83 kg; 0.24 mg/kg for patients weighing > 83 kg; by subcutaneous injection once daily.
  • Children: 0.24 mg/kg body weight subcutaneously.
  • Given 6 to 11 hours before each apheresis after 4 days of G-CSF pre-treatment; commonly used for 2 to 4 (up to 7) consecutive days.
  • The dose should not exceed 40 mg/day.
  • Creatinine clearance 20-50 ml/min: reduce to 0.16 mg/kg/day, not exceeding 27 mg/day; no recommendation below 20 ml/min or on haemodialysis.

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients.

Important warnings

  • Not recommended for stem cell mobilisation in leukaemia, as leukaemic cells may be mobilised and contaminate the apheresis product.
  • Increases circulating leukocytes; white blood cell counts should be monitored, and platelet counts checked in all patients undergoing apheresis.
  • Allergic reactions, including anaphylactic shock, and vasovagal reactions, orthostatic hypotension or syncope can occur after injection.
  • Splenomegaly and splenic rupture have been reported.

Side effects

  • Very common: diarrhoea, nausea, injection site reactions.
  • Common: insomnia, dizziness, headache, vomiting, abdominal pain, dyspepsia, constipation, flatulence, dry mouth, hyperhidrosis, erythema, arthralgia, musculoskeletal pain, fatigue, malaise.
  • Uncommon: allergic reaction, abnormal dreams, nightmares. Not known: splenomegaly, splenic rupture, anaphylactic reactions.

Interactions

  • No interaction studies; plerixafor is not metabolised by CYP enzymes and does not inhibit or induce them.
  • Adding rituximab did not affect safety or CD34+ cell yield in non-Hodgkin's lymphoma.

Pregnancy and breastfeeding

  • Plerixafor is suggested to cause congenital malformations; it should not be used during pregnancy unless clinically required, and women of childbearing potential must use effective contraception.
  • Breast-feeding should be discontinued during treatment.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

Source: European Medicines Agency (EMA), product information

Austria

  • Plerixafor StadaStada Arzneimittel Gmbh · 1 register entry
  • Plerixafor TevaRatiopharm Arzneimittel Vertriebs-Gmbh · 1 register entry
  • Plerixafor ViatrisViatris Limited · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • Plerixafor AmaroxAmarox Pharma Gmbh · 1 register entry
  • Plerixafor PurenEugia Pharma (Malta) Limited · 1 register entry
  • Plerixafor RatiopharmRatiopharm Gmbh · 1 register entry
  • Plerixafor SeacrossSeacross Pharma (Europe) Ltd · 1 register entry
  • Plerixafor StadaStadapharm Gmbh · 1 register entry
  • Plerixafor TillomedTillomed Pharma Gmbh · 1 register entry
  • Plerixafor ViatrisViatris Germany Gmbh · 1 register entry
  • Plerixafor VivantaVivanta Generics S.R.O. · 1 register entry
  • Plerixafor ZentivaZentiva Pharma Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • LexevaTEVA İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • MiyeleksorVEM İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • MozobilSANOFİ SAĞLIK ÜRÜNLERİ LTD. ŞTİ. · 1 register entry
  • MozoforPOLİFARMA İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • MozosentSENTINUS İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • PleksorGEN İLAÇ VE SAĞLIK ÜRÜNLERİ SAN. VE TİC. A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 22 more European countries
Bulgaria
Plerixafor Msn
Croatia
Pleriksafor Msn, Pleriksafor Onkogen, Pleriksafor Sandoz, Pleriksafor Teva
Czechia
Pleforbil, Plerixafor Msn
Denmark
Plerixafor Seacross, Plerixafor Teva, Plerixafor Viatris, Plerixafor Vivanta
Estonia
Plerixafor Auxilia
Finland
Plerixafor Seacross, Plerixafor Viatris, Plerixafor Vivanta
France
Plerixafor Arrow, Plerixafor Seacross, Plerixafor Teva, Plerixafor Tillomed, Plerixafor Viatris, Plerixafor Zentiva, Plérixafor Eg
Hungary
Plerixafor Msn, Plerixafor Onkogen, Plerixafor Teva
Iceland
Mozobil, Plerixafor Accord, Plerixafor Viatris
Ireland
Plerixafor Msn Labs Europe, Plerixafor Seacross
Italy
Plerixafor Aurobindo, Plerixafor Eg, Plerixafor Seacross, Plerixafor Teva, Plerixafor Tillomed, Plerixafor Viatris
Liechtenstein
Mozobil, Plerixafor Accord
Lithuania
Plerixafor Auxilia
Netherlands
Plerixafor Amarox, Plerixafor Sandoz, Plerixafor Seacross, Plerixafor Teva, Plerixafor Vivanta
Norway
Mozobil, Plerixafor Accord, Plerixafor Seacross, Plerixafor Teva, Plerixafor Viatris, Plerixafor Vivanta
Poland
Plerixafor Biofar, Plerixafor Msn
Portugal
Plerixafor Eugia, Plerixafor Mylan, Plerixafor Seacross, Plerixafor Teva
Romania
Plerixafor Msn Labs Europe
Slovakia
Plerixafor Msn, Plerixafor Onkogen
Slovenia
Pleriksafor Onkogen, Pleriksafor Teva
Spain
Plerixafor Eugia, Plerixafor Glenmark, Plerixafor Seacross, Plerixafor Stada, Plerixafor Tarbis, Plerixafor Vivanta
Sweden
Plerixafor Seacross, Plerixafor Teva, Plerixafor Viatris, Plerixafor Vivanta

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Mozobil – EPAR, Product Information. 2026-10-29. https://www.ema.europa.eu/en/documents/product-information/mozobil-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  5. Wikidata (CC0): ATC L03AX.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.